Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1431-1435

  Wada, Masahiro ^a   Jinno, Hiromitsu ^a   Ueda, Masakazu ^a   Ikeda, Tadashi ^b   Kitajima, Masaki ^a   Konno, Tomohiro ^c   Watanabe, Junji ^c   Ishihara, Kazuhiko ^c  

^a KEIO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

2 methacryloyloxyethyl phosphorylcholine (MPC); Co polymer; Paclitaxel (PTX); Tumour

Indexed keywords

2 METHACRYLOYLOXYETHYLPHOSPHORYLCHOLINE; COPOLYMER; DIMETHYL SULFOXIDE; METHACRYLIC ACID; PACLITAXEL; PMB 30 W; RICINOMACROGOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SOLUBILITY; EXTRAVASATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; SKIN ULCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIMETHYL SULFOXIDE; DRUG CARRIERS; FEMALE; HUMANS; METHACRYLATES; MICE; MICE, NUDE; NANOCAPSULES; PACLITAXEL; PHOSPHORYLCHOLINE; SKIN; SKIN ULCER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34249294536     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Crown J and O'Leary M: The taxanes: an update. Lancet 355: 1176-1178, 2000.
2. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD and Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268, 1990.
3. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K and Colombo N: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
4. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD and Thirlwell MP: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 17: 3403-3411, 1999.
5. Socinski MA, Mudd PN Jr, Radomski KM, Steagall A, Lawrence P, Bernard S, Letrent SP, Gonzalez P and Brouwer KL: Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Anticancer Drugs 9: 611-619, 1998.
6. Finley RS and Rowinsky EK: Patient care issues: the management of paclitaxel-related toxicities. Ann Pharmacother 28: S27-S30, 1994.
7. TAXOL® (Paclitaxel) INJECTION. Patient information leaflet. Bristol-Myers Squibb Company, Princeton, U.S.A., 2003.
8. Ishihara K, Oshida H, Endo Y, Ueda T, Watanabe A, and Nakabayashi N: Hemocompatibility of human whole blood on polymers with a phospholipid polar group and its mechanism. J Biomed Mater Res 26: 1543-1552, 1992.
9. Singer SJ and Nicolson GL: The fluid mosaic model of the structure of cell membranes. Science 175: 720-731, 1972.
10. Ishihara K, Aragaki R, Ueda T, Watanabe A and Nakabayashi N: Reduced thrombogenicity of polymers having phospholipid polar groups. J Biomed Mater Res 24: 1069-1077, 1990.
11. Moro T, Takatori Y, Ishihara K, Konno T, Takigawa Y, Matsushita T, Chung UI, Nakamura K and Kawaguchi H: Surface grafting of artificial joints with a biocompatible polymer for preventing periprosthetic osteolysis. Nat Mater 3: 829-836, 2004.
12. Konno T, Watanabe J and Ishihara K: Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A 65: 209-214, 2003.
13. Kubota T, Kubouchi K, Koh J, Enomoto K, Ishibiki K and Abe O: Human breast carcinoma (MCF-7) serially transplanted into nude mice. Jpn J Surg 13: 381-384, 1983.
14. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
15. Geran RI Greenberg NH, Macdonald MM, Schumacher AM and Abbott BJ: Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems. 3rd ed., National Cancer Institute, National Institute of Health, Bethesda, 1972.
16. Ishihara K, Takayama R, Nakabayashi N, Fukumoto K and Aoki J: Improvement of blood compatibility on cellulose dialysis membrane. 2. Blood compatibility of phospholipid polymer grafted cellulose membrane. Biomaterials 13: 235-239, 1992.
17. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN and Ellerhorst JA: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8: 1038-1044, 2002.
18. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Saughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7794-7803, 2005.
19. Konno T, Watanabe J and Ishihara K: Conjugation of enzymes on polymer nanoparticles covered with phosphorylcholine groups. Biomacromolecules 5: 342-347, 2004.
20. Takei K, Konno T, Watanabe J and Ishihara K: Regulation of enzyme-substrate complexation by a substrate conjugated with a phospholipid polymer. Biomacromolecules 5: 858-862, 2004.
21. Shimada T, Ueda M, Ikeda T, Jinno H, Watanabe J, Ishihara K and Kitajima M: Development of targeted therapy with paclitaxel incorporated in an EGF-conjugated nanoparticle. Proc Amer Assoc Cancer Res 46: Abstract 4393, 2005.